CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Active, not recruiting · NCT04718883 · Registry updated 2023-11-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2023-11-24 | NCT04718883 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Ming Ju Biotechnology Co., Ltd. | 7 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | China | 85 |
| Fujian Medical University Consonancy Hospital | Fuzhou | China | 1 |
| Guangdong Province people hospital | Guanzhou | China | 1 |
| Henan Province Cancer Hospital | Zhengzhou | China | 1 |
| Institute of Hematology, Chinese Academy of Medical Sciences | Tianjin | China | 2 |
| Jiangsu Province People Hospital | Nanjing | China | 1 |
| Peking University Cancer Hospital | Beijing | China | 2 |
| Peking University Third Hospital | Beijing | China | 38 |
| The First Affiliated Hospital of Zhejiang University | Hangzhou | China | 4 |
| Tianjin Cancer Hospital | Tianjin | China | 14 |
| Zhejiang Province Cancer Hospital | Hangzhou | China | 2 |
| Zhongshan Hospital Affiliated to Fudan University | Shanghai | China | 10 |